Brett Edward Houk

From Wikitia
Jump to navigation Jump to search
Brett Edward Houk
Add a Photo
NationalityAmerican
CitizenshipUnited States of American
EducationDoctorate in pharmacy
Alma materUniversity of Florida
OccupationClinical pharmacologist,Pharmaceutical scientist

Dr. Brett Edward Houk is an american clinical pharmacologist and pharmaceutical scientist, currently a Director of Clinical Pharmacology Modeling and Simulation at Amgen[1]. Dr. Houk is also a significant figure in his field, having published over 73 papers with over 2000 citations[2]. He has contributed to the development of multiple pharmaceutical agents including Enbrel.[3], Sutent[4] [5] [6] [7], Inlyta[8], Lobrena, gedatolisib [9] [10] [11] [12] and sotorasib (AMG510). He is most notably recognized for his contributions to the field of pharmacokinetic/pharmacodynamic modeling of anti-cancer agent therapy [13] and gene therapy. [14]

Education

Houk holds a doctorate in pharmacy from the University of Florida [1], where his published dissertation work focused on pharmacokinetics of gene therapy[15][16].

Publications

Houk has published over 73 scientific publications with an h-index of 18 and an i10-index of 24[17], published a book chapter[18] given presentations at national or international meetings including ASCO,and serves on the editorial board of several journals.

References

  1. ↑ https://www.researchgate.net/profile/Brett_Houk2
  2. ↑ https://scholar.google.com/citations?user=mpeNezsAAAAJ&hl=en&oi=ao
  3. ↑ Houk, B. (2004). "Modeling of placebo drug effect using a population pharmacodynamic mixture model". Clinical Pharmacology & Therapeutics. 75 (2): P97. doi:10.1016/j.clpt.2003.11.372.
  4. ↑ https://clincancerres.aacrjournals.org/content/early/2020/06/10/1078-0432.CCR-20-0887.full-text.pdf
  5. ↑ https://mct.aacrjournals.org/content/6/11_Supplement/C190
  6. ↑ Houk, B. E.; Bello, C. L.; Michaelson, M. D.; Bukowski, R. M.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Motzer, R. J. (2007). "Exposure-response of sunitinib in metastatic renal cell carcinoma (MRCC): A population pharmacokinetic/Pharmacodynamic (PKPD) approach". Journal of Clinical Oncology. 25 (18_suppl): 5027. doi:10.1200/jco.2007.25.18_suppl.5027.
  7. ↑ https://academic.oup.com/jjco/article/40/3/194/854512
  8. ↑ https://www.researchgate.net/publication/295273405_A_population_pharmacokinetic_PK_analysis_to_evaluate_the_potential_effect_of_the_UGT1A128_genotype_on_the_PK_of_AG-013736_an_anti-angiogenic_agent
  9. ↑ Wainberg, Zev A.; Shapiro, Geoffrey; Curigliano, Giuseppe; Kristeleit, Rebecca Sophie; Leong, Stephen; Alsina, Maria; Milella, Michele; Britten, Carolyn D.; Gelmon, Karen A.; Olszanski, Anthony J.; Vaishampayan, Ulka N.; Lopez-Martin, Jose A.; Kern, Kenneth Alan; Pierce, Kristen J.; Perea, Rachelle; Houk, Brett; Pathan, Nuzhat; Razak, Albiruni R. (2016). "Phase I study of the PI3K/MTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib". Journal of Clinical Oncology. 34 (15_suppl): 2566. doi:10.1200/JCO.2016.34.15_suppl.2566.
  10. ↑ Forero-Torres, Andres; Han, Heather; Dees, Elizabeth Claire; Wesolowski, Robert; Bardia, Aditya; Kabos, Peter; Layman, Rachel M.; Lu, Janice M.; Kern, Kenneth Alan; Perea, Rachelle; Pierce, Kristen J.; Houk, Brett; Pathan, Nuzhat; Rugo, Hope S. (2018). "Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009)". Journal of Clinical Oncology. 36 (15_suppl): 1040. doi:10.1200/JCO.2018.36.15_suppl.1040.
  11. ↑ https://www.gynecologiconcology-online.net/article/S0090-8258(16)30151-2/abstract
  12. ↑ https://cancerres.aacrjournals.org/content/78/4_Supplement/OT2-07-06
  13. ↑ https://www.springer.com/gp/book/9781441979360
  14. ↑ Houk, Brett E.; Hochhaus, Gunther; Hughes, Jeffrey A. (1999). "Kinetic modeling of plasmid DNA degradation in rat plasma". AAPS Pharmsci. 1 (3): 15–20. doi:10.1208/ps010309. PMC 2761123. PMID 11741205.
  15. ↑ https://www.springer.com/gp/book/9781441979360
  16. ↑ Houk, Brett E.; Hochhaus, Gunther; Hughes, Jeffrey A. (1999). "Kinetic modeling of plasmid DNA degradation in rat plasma". AAPS Pharmsci. 1 (3): 15–20. doi:10.1208/ps010309. PMC 2761123. PMID 11741205.
  17. ↑ https://scholar.google.com/citations?user=mpeNezsAAAAJ&hl=en&oi=ao
  18. ↑ https://www.springer.com/gp/book/9781441979360

This article "Brett Edward Houk" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.

Retrieved from "https://wikitia.com/index.php?title=Brett_Edward_Houk&oldid=72437"